New cocktail of drugs shows promise for Tough-to-Treat colon cancer
NCT ID NCT03290937
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of three drugs—utomilumab, cetuximab, and irinotecan—in 34 patients with advanced colorectal cancer that had spread and stopped responding to standard treatment. The goal was to find the safest dose and check for side effects. While the approach aims to boost the immune system and attack cancer cells directly, it is still very early research and not yet proven to work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
utomilumab, cetuximab, and irinotecan hydrochloride
What this could lead to
If successful, this could point toward a new combination treatment option for advanced colorectal cancer that has stopped responding to standard chemotherapy.
What could go wrong
This is a very early phase I trial with only 34 participants, focused on finding the right dose and checking safety. It is too small to prove whether the combination actually works, and side effects may be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV COLORECTAL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States